Basic elements of ethnopsychopharmacology;Elementos básicos de etnopsicofarmacología

Actas Espanolas de Psiquiatria

Volumn 31, Issue 3, 2003, Pages 156-162

  García Campayo, Javier ^a   Alda, M ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Culture; Ethnicity; Immigration; Psychopharmacology

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIAZEPAM; ENZYME; FLUOXETINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; MIDAZOLAM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; TRIAZOLAM; UNINDEXED DRUG; ZOLPIDEM;

CULTURAL ANTHROPOLOGY; DRUG EFFECT; ETHNIC GROUP; ETHNOLOGY; ETHNOPHARMACOLOGY; FOOD; HUMAN; MEDICAL PROFESSION; MEDICINE; PATIENT CARE; PSYCHOLOGY; REVIEW;

CULTURE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; EMIGRATION AND IMMIGRATION; ETHNIC GROUPS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 0042066734     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Lin KM, Cheung F. Mental health issues for Asian-Americans. Psychiatr Serv 1999;50:774-80.
2. Jensvold MF, Halbreich V, Hamilton JA. Psychopharmacology and women: sex, gender and hormones. Washington: American Psychiatric Press, 1996; p. 121-36.
3. Lin KM, Smith MW. Psychopharmacotherapy in the context of culture and ethnicity. En: Ruiz P, editor. Ethnicity and psychopharmacology. Rev Psychiatry 19; 4. Washington: American Psychiatric Press, 2000; p. 1-36.
4. Centers for Disease Control and Prevention (CDCP) (June 25, 1993). Use of race and ethnicity in public health surveillance. Morb Mort Weekley Rep 42 (RR-10);11-2.
5. Hautman MA, Bomar P. Interactional model of recruiting ethnically diverse research participants. J Multicult Nurs Health 1995;1:8-15.
6. Masimirembwa CM, Hasler JA. Genetic polymorphism of drug metabolising enzimes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997;44:561-71.
7. Lin KM, Smith MW, Ortiz V. Culture and psychopharmacology. Psychiatr Clinics North Am 2001;24:523-38.
8. Kroemer HK, Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P-450 2D6 polymorphism. Life Sci 1995;56:2285-98.
9. Daly AK, Brockmoller J, Broly F. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
10. Guengerich FP, Shimada T, Yun CH. Interactions of ingested food, beverage, and tobacco components involving human citocrome p-4501A2, 2A6, 2E1, and 3A4 enzimes. Environ Health Perspect 1994;102(Suppl 9):49-53.
11. Anderson KE, Kappas A. Dietary regulation of cytochrome P450. Annu Rev Nutr 1991;11:141-67.
12. Fuhr U, Klittich K, Staib AH. Inhibitory effects of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993;35:431-6.
13. Piscitelli SC, Burstein AH, Chaitt D. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8.
14. García-Campayo J, Sanz Carrillo C. The use of alternative medicines by somatoform disorder patients in Spain. Br J Gen Pract 2000;50:487-8.
15. Ekblad S, Kohn R, Jansson B. Psychological anti clinical aspects of immigration and mental health. En: Clinical methods in transcultural psychiatry. SO Okpaku. Washington: American Psychiatric Press, 1998; p. 42-68.
16. Smith N, Lin KM, Mendoza R. «Non-biological» issues affecting psychopharmacotherapy: Cultural considerations. En: KM Lin, R Poland, G Nagasaki, editores. Psychopharmacology and psychobiology of ethnicity. Washington: American Psychiatric Press, 1993; p. 37-58.
17. Chen A. Noncompliance in community psychiatry: a review of clinical interventions. Hosp Com Psychiatry 1991;42:282-7.
18. Sackett D, Haynes R. Compliance with therapeutic regimens. Baltimore: John Hopkins University Press, 1976.
19. Fenton WS, Blyler CR, Herinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
20. Sue S, Fujino DC, Hu LT. Community mental health services for ethnic minority groups: a test of the cultural responsiveness hypothesis. J Consult Clin Psychol 1991;59: 533-40.
21. Díaz L, Jacobsen FM. Ethno-cultural transference and countertransference in the therapeutic dyad. Am J Orthopsychiatry 1991;61:392-402.
22. Spiegel JP. Cultural aspects of transference and countertransference revisited. J Am Acad Psychoanal 1976;4:447-67.
23. Strickland TL, Lawson W, Lin KM, Fu P. Interethnic variation in response to lithium therapy among African-American and Asian-American populations. En: Lin KM, Poland RE, Nakasaki G, editores. Psychopharmacology and psychobiology of ethnicity. Progress in psychiatry 39. Washington: American Psychiatric Press, 1994; p. 107-21.
24. Gillis L, Trollip D, Jakoet A, et al. Non-compliance with psychotropic medication. S Afr Med J 1987;72:602-6.
25. Kleinman A. Rethinking psychiatry. New York: Free Press, 1988.
26. Weiss M. Explanatory model interview catalogue (EMIC): Framework for comparative studies of illness. Transc Psychatr 1997;34:235-63.
27. Acosta FX, Yamamoto J, Evans LA. Effective psychotherapy for low-income and minority patients. New York: Plenum; 1982.
28. White L, Turskey B, Scwartz GE. Placebo: theory, research and mechanisms. New York: Guifford, 1985.
29. Bucklelow LW, Coffield K. Drug expectations associated with perceptual characeristics: ethnic factors. Percept Mot Skills 1982;55:915-8.
30. Lee S, Wing YK, Wong KC. Knowledge and compliance towards lithium therapy among Chinese psychiatric patients in Hong Kong. Aust NZ J Psychiatry 1992;26:444-9.
31. Paradis CM, Hatch M, Friedman S. Anxiety disorders in African Americans: an update. J Nat Med Assoc 1994;86:609-12.
32. Lawson WB. Psychiatric diagnosis of African Americans. En: Herrera JM, Lawson WB, Sramek JJ, editores. Cross-cultural Psychiatry. New York: Wiley, 1999; p. 99-104.
33. Frueh BC, Smith DW, Libet JM. Racial differences on psychological measures in combats with veterans seeking treatment for PTSD. J Pers Assess 1996;66:41-53.
34. Strickland T, Binganath V, Lin KM. Psychopharmacological considerations in the treatment of black American population. Psychopharmacol Bull 1991;27:441-8.
35. Strakowsky SM, Lonczak HS, Sax K. The effect of race in diagnosis And disposition from a psychiatric emergency service. J Clin Psychiatry 1995;56:101-7.
36. Adebimpe VR. Race, racism and epidemiological surveys. Hosp Com Psychiatr 1994;45:27-31.
37. Kessler RC, McGonaole K, Zhao S. Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.
38. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatr 1995;56(Suppl 3);25-30.
39. Jones BE, Gray BA. Problems in diagnosing schizophrenia and affective disorders among blacks. Hosp Com Psychiatr 1986;37:61-5.
40. Lawson WB. Racial and ethnic factors in psychiatric research. Hosp Com Psych 1986;37:50-4.
41. Silver B, Poland RE, Lin KM. Ethnicity and the pharmacology of tricyclic antidepressant. En: Lin KM, Poland RE, Nakasatu G, editores. Psychopharmacology and psychobiology of ethnicity. Washington: American Psychiatric Association, 1993; p. 61-89.
42. Livingston RL, Zucker D, Isenberg K. Tryciclic antidepressants and delirium. J Clin Psychiatr 1983;44:173-6.
43. Mendoza RP, Smith MV, Lin KM. Ethnicity and the pharmacogenetics of drug-metabolizing enzymes. En: Herrera JM, Lawson WB, Sramek JJ, editores. Cross-cultural psychiatry. New York: Wiley, 1999; p. 3-15.
44. Littlewwod R. Psychiatric diagnosis and racial bias: empirical and interpretative approachs. Soc Sci Med 1992;34:141-9.
45. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002;159:567-72.
46. Harris M. La cultura norteamericana contemporánea. Una visi6n antropológica. Madrid: Alianza Editorial, 1988.
47. Chung H, Mahler JC, Kakuna T. Racial differences in the treatment of psychiatric patients. Psychiatr Serv 1995; 46:585-9.
48. Rosenheck R, Fontana A, Cottrol C. Effect of clinician-veteran racial pairing in the treatment of PTED. Am J Psychiatry 1995;152:555-63.
49. Pi EH, Gutiérrez M, Gray GE. Tardive-dyskinesia: cross-culutral perspectives. En: Psychopharmacology and psychobiology of ethnicity. Lin KM, Poland RE, Nakasaki L, editores. Washington: APA, 1993; p. 153-67.
50. Jarvis E. Schizophrenia in British immigrants: recent findings, issues and implications. Transc Psychiatry 1998;35:39-74.
51. Selten JP, Slaets JPJ, Kahn RS. Schizophrenia in Surinamese and Ducth Antillean immigrants to the Netherlands: evidence of an increased incidence. Psychol Med 1997;27:807-11.
52. Mortensen PB, Cantor-Graae E, McNeil TF. Increased rates of schizophrenia among immigrants: some methodological concerns raised by Danish findings. Psychol Med 1997;27:813-20.
53. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Com Psychiatry 1994;45:38-42.
54. Awartz R, Burgoyne K, Smith M. Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiatry 1998;9:53-9.
55. Lindamer L, Lacro JP, Jeste DV. Relationship of ethnicity to the effects of antipsychotic medication. En: Herrera JM, Lawson WB, Srameck JJ, editores. Cross-cultural psychiatry. New York: Wiley, 1999; p. 193-203.
56. Karayalcin G, Rosner F, Sawitsk-y A. Pseudoneutropenia in negroes: a normal phenomenon. NY State Med J 1972;72:1815-7.
57. Moeller FG, Chen YW, Steinberg JL. Risk factors for clozapine discontinuation in among 805 patients in the VA hospital system. Ann Clin Psychiatry 1995;7:163-73.
58. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother 1982;36:505-13.
59. Mendoza R, Smith MW. The Hispanic response to psychotropic medications. En: Ruiz R, editor. Ethnicity and psychopharmacology. Review of Psychiatry 19; 4. Washington: American Psychiatric Press, 2000; p. 55-90.
60. Alonso M, Val E, Rapaport MH. An open-label study of SRRI treatment in depressed Hispanic and non-Hispanic women. J Clin Psychiatry 1997;58:31.
61. Versiani M, Ontiverso A, Mazzoti G. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety: a double blind comparison. En: Herrera JM, Lawson WB, Sramek JJ, editores. Cross-cultural psychiatry. New York: Wiley, 1999; p. 249-58.
62. Collazo Y, Tam R, Sramek J. Neuroleptic dosing in Hispanic and Asian patients with schizophrenia. Mt Sinai J Med 1996;63:310-3.
63. Ruiz S, Chu P, Sramek J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996;63:306-9.
64. Ramírez L. Ethnicity and psychopharmacology in Latin America. Mt Sinai J Med 1996;63:330-1.
65. Tran P, Tohen M, Mazzoti G. Switching psychotic patients with symptomatic extrapiramidal symptoms from haloperidol to olanzapine: results of a multicenter collaborative trial in Latin America. Paper presented at the Annual meeting of the American Psychiatric Association, Toronto, Canadá, 1998.
66. Frackiewicz E, Sramek J, Collazo Y. Risperidone in the treatment of Hispanic schizophrenic patients. En: Herrera JM, Lawson WB, Sramek JJ, editores. Cross-cultural psychiatry. New York: Wiley, 1999; p. 183-92.
67. Ajir K, Smith M, Lin KM. The pharmacokinetics and pharmacodynamics of adinazolam in multi-ethnic comparisons. Psychopharmacology 1997;129:265-70.
68. Sramek JJ, Pi EH. Antidepressants response in ethnic population. En: Herrera JM, Lawson WB, Sramek JJ, editores. New York: Wiley, 1999; p. 207-19.
69. Pi EH, Gray GE. A cross cultural perspective on psychopharmacology. Essential Psycopharmacology 1998;2:233-62.
70. Sung SK, Lee CM, Young JD. High levels of tyramine in some Chinese foodstuffs. Human Psychopharmacol 1986;1:103-7.
71. Whitford GM. Acetylator phenotype in relation to MAOI drug therapy. Intern Pharmacopsychiatr 1978;31:126-32.
72. Pi EH, Jain A, Simpson GM. Review and survey of different prescribing practices in Asia. En: Shiagaso C, Josiasson RC, editores. Biological psychiatry. New York: Elsevier, 1985; p. 1536-8.
73. Lin KM, Poland RE, Lav JC. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988;8:195-201.
74. Matsuda LT, Cho MC, Lin KM. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996;32:253-7.
75. Binder RL, Levy R. Extrapiramidal reactions in Asians. Am J Psychiatry 1981;138:1243-4.
76. Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Austr NZ J Psychiatry 1991;25:119-22.